Oncology Drugs

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

Novartis unveils groundbreaking Phase III data for Rhapsido, offering hope as the first potential targeted therapy for 29 million chronic hive sufferers.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

As youth nicotine pouch use soars, Imperial Tobacco Canada calls for a crackdown on illicit sales. But is this a genuine public health plea or a masterful play to secure its market?

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

With over 55,000 on waitlists for the UK's first oral weight-loss pill, the market is set to explode. But strict rules and high hopes face a reality check.

In memory of her daughter Elora, a mother's foundation joins a global research network, turning personal tragedy into a collaborative fight against a rare cancer.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

A novel case study reveals how targeted chemotherapy delivery is outsmarting stubborn tumors, highlighting a metabolic victory even when size remains unchanged.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.